GPX4 and osteoarthritis: In this study, the SIRT3 agonist (0.05 μM of SRT 1720 dihydrochloride) was used to induce SIRT3 and GPX4 protein expressions and attenuate the effects of si-PRDX3 on ROS accumulation in the in vitro osteoarthritis model (Figure 7A-G).